Merck Sharp & Dohme Llc

This early-stage study is testing a new vaccine called V118E to see if it is safe and well-tolerated in healthy adults. The vaccine aims to protect against infections caused by Streptococcus pneumoniae bacteria, which can cause pneumonia and other serious illnesses. Around 126 he…

This study tests a new dengue vaccine called V181 in 12,000 healthy children aged 2 to 17. The goal is to see if the vaccine is safe, triggers a strong immune response, and reduces cases of dengue fever caused by any of the four dengue virus types. Participants will receive eithe…

This early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus (EBV), which can cause infectious mononucleosis and is linked to certain cancers and multiple sclerosis. The study will enroll 250 healthy adults and…

This early-stage trial is testing a new vaccine called V118C to prevent pneumococcal disease, which can cause serious lung and other infections. About 210 toddlers and infants will receive either V118C or an existing vaccine to compare safety and immune response. The study is cur…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated foll…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About 1,04…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This study tests whether tulisokibart can improve symptoms of radiographic axial spondyloarthritis, a type of arthritis that causes pain and swelling in the spine and pelvis. About 315 adults with active disease will receive either the drug or a placebo for 16 weeks. Researchers …

This phase 3 trial is testing a drug called tulisokibart in about 1,200 people with moderate-to-severe Crohn's disease who haven't had success with other treatments. The drug is given by IV or injection and aims to reduce symptoms and heal the gut lining. The study compares tulis…

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma. About 594 adults who have no…

This Phase 2 trial tests whether adding a personalized mRNA vaccine (V940) to standard pembrolizumab and chemotherapy helps people with newly diagnosed metastatic squamous non-small cell lung cancer live longer and keep the cancer from growing. About 180 participants will receive…

This study tests a new targeted therapy pill called MK-1084, alone or with other drugs, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if the treatment is safe and can shrink tumors. About 130 participan…

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This long-term study follows people with pulmonary arterial hypertension (PAH) who previously took part in sotatercept trials. Sotatercept is a targeted therapy that aims to stop PAH from getting worse. Researchers will monitor safety, side effects, and how well patients tolerate…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…

This phase 3 trial is testing a new oral drug, nemtabrutinib, against two standard targeted therapies (ibrutinib or acalabrutinib) in 1,200 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if nemtabrutinib works at least as well…

This study tests whether a combination of two oral drugs, belzutifan and zanzalintinib, works better than the current standard drug cabozantinib for people with advanced kidney cancer that has come back after prior treatment. About 904 participants will be randomly assigned to on…

This study tests whether adding an experimental drug (MK-3120) to the standard treatment (enfortumab vedotin plus pembrolizumab) is safe and effective for people with advanced bladder cancer that has spread. About 55 participants will receive the new combination. Researchers will…

This Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…

This phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …

This study tests several new drug combinations, with or without the immunotherapy pembrolizumab, in people with advanced esophageal cancer that has continued to grow after standard treatment. About 230 participants will receive different drug regimens to see which are safest and …

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This phase 3 trial compares bomedemstat, an experimental oral drug, to hydroxyurea (standard therapy) in 300 people with essential thrombocythemia who have not yet received cytoreductive treatment. The goal is to see if bomedemstat better controls platelet counts and prevents com…

This study tests whether the antiviral drug molnupiravir can prevent severe illness from COVID-19 in adults at high risk. About 3,000 non-hospitalized participants will take either molnupiravir or a placebo for 5 days. The main goal is to see if the drug reduces hospitalizations,…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can eliminate all signs of cancer in people with resectable stage II to IIIB non-small cell lung cancer. About 60 participants will receive the comb…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…

This study tests an experimental drug called MK-2214 in 340 people with early Alzheimer's disease. The goal is to see if it can slow the buildup of a harmful protein called tau in the brain, which damages brain cells. Participants will receive either the drug or a placebo, and re…

This phase 3 trial tests whether the experimental drug sacituzumab tirumotecan helps people with advanced bladder cancer live longer than standard chemotherapy. About 590 participants whose cancer worsened after prior treatments will receive either the new drug or one of several …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests a daily pill called enlicitide decanoate in 153 children and teens with heterozygous familial hypercholesterolemia (HeFH), a genetic condition causing very high cholesterol. The goal is to see if the drug safely lowers LDL cholesterol more than a placebo. Researc…

This study tests several new drug combinations, including pembrolizumab (an immunotherapy), with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combinations can shrink tumors and control th…

This study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tu…

This Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killi…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This study tests whether the drug vericiguat can help children with heart failure caused by a weak left heart chamber. About 342 children aged 1 month to 18 years will receive either vericiguat or a placebo for 16 weeks. The main goal is to see if the drug lowers a key heart stre…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …

This phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappe…

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…

This study is testing the drug letermovir to prevent cytomegalovirus (CMV) infection in children and teens who have had a kidney transplant and weigh less than 40 kg. About 40 participants will receive the drug to see how it moves through their bodies and if it is safe. The goal …

This study tests whether MK-8690, a drug given as a shot, can help people with moderate-to-severe ulcerative colitis achieve remission. About 100 adults who haven't responded well to other treatments will receive either MK-8690 or a placebo. The main goal is to see if more people…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a catheter. The main goals are to find the safest dose and see if people can toler…

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests whether a once-weekly combination of two experimental drugs (islatravir and ulonivirine) works as well as the standard daily three-drug pill Biktarvy for people newly diagnosed with HIV-1. About 570 adults who have never taken HIV medication will be randomly assi…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This early-stage study tests an experimental drug called MK-1403 in people with type 2 diabetes. The main goals are to check if the drug is safe and tolerable, and to see how it behaves in the body. Researchers will also measure its effect on a marker of inflammation (hsCRP). Abo…

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

This phase 2 trial is testing whether adding a targeted drug called HER3-DXd to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different combinations…

This phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…

This early-phase trial is testing a new drug called zilovertamab vedotin, alone or with the immunotherapy pembrolizumab, in 48 people with advanced bladder cancer that no longer responds to standard PD-1/L1 inhibitors. The study aims to see if the treatment is safe and can shrink…

This clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…

This study tests experimental drug combinations for people with advanced kidney cancer (clear cell type) that came back during or within 2 years of finishing immunotherapy. About 140 participants will receive these combinations to see if they are safe and can shrink tumors. The g…

This study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …

This study tests a drug called patritumab deruxtecan in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. About 81 adults will take part. This is not a cure, but aims to co…

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This study looks at the long-term safety of a medicine called tulisokibart for people with moderate to severe Crohn's disease or ulcerative colitis. It is an extension study, meaning participants must have already taken tulisokibart in a previous study. The main goal is to see ho…

This phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…

This study tests MK-5684, a drug that blocks the body from making steroid hormones, in people with breast, ovarian, or endometrial cancer. Researchers want to see if it helps patients live longer without their cancer growing compared to standard treatments. The trial is recruitin…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …

This study tests an HIV medicine called doravirine in children aged 4 weeks to under 12 years who weigh less than 45 kg. The goal is to see how the drug works in their bodies and if it is safe. About 84 children who are either new to treatment or already have the virus under cont…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This study tests a drug called sotatercept in 42 children aged 1 to 18 who have pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work too hard. The drug is given as a shot every 3 weeks, and the main goal is to see if it is safe and how the bod…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This study follows about 400 people with certain blood cancers (like essential thrombocythemia and myelofibrosis) who are already taking bomedemstat and benefiting from it. The goal is to collect more information on the drug's long-term safety and how well it controls the disease…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study is testing the antifungal drug posaconazole in infants under 2 years old who have a serious fungal infection. The goal is to find out how the drug moves through the body and what dose is safe. About 40 infants will receive the drug either through an IV or as a powder m…

This phase 3 trial tests MK-8527, a once-monthly oral pill, to prevent HIV-1 infection in women. About 4580 HIV-negative women will take either MK-8527 monthly or a daily PrEP pill (Truvada) to see which works better and is safer. The goal is to offer a more convenient prevention…

This large phase 3 trial is testing whether a new oral pill called MK-8527, taken just once a month, can prevent HIV infection as well as the standard daily PrEP pill. About 4,390 people at risk of HIV will be randomly assigned to receive either the monthly pill or daily Truvada …

This study tests whether suvorexant, a sleep medication, can help people with opioid use disorder fall asleep and stay asleep. About 300 participants will receive either suvorexant or a placebo. The goal is to see if the drug improves total sleep time and is safe to use.

This early-stage study will give 30 healthy volunteers single doses of two experimental drugs, MK-7262 and enlicitide, to see how they affect each other's levels in the blood. The goal is purely to understand how the drugs interact, not to treat any disease. Results will guide fu…

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. The goal is to see which treatments work best based on specific tumor features like PD-L1 levels and histology. Over 1,000 …

This study is for 60 healthy adults to see how the body processes two medicines—enlicitide and rosuvastatin—when taken as separate pills versus combined into one tablet. Researchers will measure drug levels in the blood over time and check for any side effects. The goal is to und…

This early-stage study tests how a single dose of MK-8527 changes the way methadone moves through the body. It involves 14 healthy adults and aims to measure methadone levels over 24 hours. The results will help understand if MK-8527 affects methadone, which is important for futu…

This early-stage study is testing a single dose of the drug MK-2828 in 24 people with different levels of kidney function, including those with severe kidney failure or on dialysis. The goal is to measure how the drug moves through the body over time and compare it to healthy vol…

This study looks at how two drugs interact in healthy adults. In Part 1, researchers measure how itraconazole changes the levels of MK-2828 in the body. In Part 2, they see if taking MK-2828 multiple times affects how the body handles a single dose of midazolam. The goal is to ga…

This study looks at how the drug MK-1084 (calderasib) moves through the body in people with and without liver problems. Researchers will measure drug levels in the blood and check for side effects. About 58 adults will take a single dose and be monitored. The goal is to understan…

This early-stage study looks at how the experimental drug nemtabrutinib is processed in people with moderate liver impairment compared to healthy volunteers. About 32 adults will receive a single oral dose, and researchers will measure drug levels in the blood over time. The goal…